BAM
TBPH icon

Blueshift Asset Management’s Theravance Biopharma TBPH Stock Holding History

Blueshift Asset Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-53,127
Closed -$393K – 1211
2021
Q3 		$393K Buy
+53,127
New +$594K 0.02% 717

Other funds holding TBPH

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

Blueshift Asset Management's TBPH Position: Q4 2021 in Review

Blueshift Asset Management sold out of Theravance Biopharma (TBPH) in Q4 2021, closing a stake of 53,127 shares — an estimated $393K sold.

Blueshift Asset Management first reported a position in TBPH in Q3 2021 and held it in 1 quarter. The position peaked at $393K in Q3 2021. 116 funds tracked by Wall St. Rank hold TBPH as of Q4 2021.

  • Blueshift Asset Management reported no remaining Theravance Biopharma position as of Q4 2021 after selling out during the quarter.
  • Blueshift Asset Management sold 53,127 Theravance Biopharma shares in Q4 2021, an estimated $393K.
  • Blueshift Asset Management first reported a position in Theravance Biopharma in Q3 2021 and held it in 1 quarter.
  • Blueshift Asset Management's Theravance Biopharma position peaked at $393K in Q3 2021.
  • 116 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2021.

Based on Blueshift Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.